Why Now Is The Time To Consider These 4 'Fallen Angel' Stocks

 | Nov 27, 2017 05:57AM ET

There are two reasons why we often see great buys in November and December, at least for the short to intermediate term.

First, individual investors owning what they believe (or believed!) to be quality companies have looked on hungrily as they see other companies’ share prices move forward rapidly. They look at their own holdings and, if they don’t see the same “action” often sell their shares to take what is often greater risk at a higher valuation, buying the momentum darlings that are moving up instead of stagnating or moving down.

Second, in a great year like 2017 has been, lots of investors have taken significant capital gains already or are planning to. When they talk to their accountant or plug this into their tax software, they suddenly realize they just pushed themselves into a higher bracket. Unless they are convinced that their now-sunk holdings are their best bet to reap further gains, it makes eminent sense for them to take whatever capital losses they must in order to return to a lower bracket.

Finally, the big mutual fund companies, managers of your pension fund, money managers, etc. do not want to look like idiots even though they may be. If you as a holder in some mutual fund, for instance, look at the year-end “Portfolio Holdings” page and see nothing but stocks that have under-performed, these managers recognize you might pull your funds and place them elsewhere. So they “window dress.”

They sell stocks not in the public eye that may represent the best long-term value and instead buy stocks that are in the news. Tesla (NASDAQ:TSLA) is a lot sexier to own than Ford (NYSE:F) and has performed reliably better in 2017 as well.

However, even if these neglected stocks that have declined were all dogs – and they are not! – “every dog shall have its day.” Market history shows that many fickle money managers, at or near the beginning of the next year, are salivating to find the Fallen Angels that will afford the best rebound probability. (This trend has moved forward in many years as more mutual funds and other institutions have moved their reporting forward for year-end.)

Here are some of my best ideas for which Fallen Angels might do best in the coming weeks and months.

h2 Health Care:/h2

Can Teva Pharmaceutical (NYSE:TEVA) make any more dumb mistakes than they already have? At first, the declines in this mega-cap generic and ethical pharmaceutical company were the result of a whole series of self-induced wounds by self-aggrandizing executives looking to secure their legacy, but now? Now it has less to do with fundamentals and more to do with the three factors stated above; having lost two-thirds of its value, now it’s just investors piling on. Could it get worse before it gets better? Any stock could. But there are patents here, and market share, that are enticing enough to make it worth your due diligence.

Get The News You Want
Read market moving news with a personalized feed of stocks you care about.
Get The App